An interventional study of Remote Blood Pressure Monitoring + Telehealth in Hypertension and Blood Pressure Monitoring, sponsored by University of Alabama at Birmingham. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypertension by University of Alabama at Birmingham — 13 open to participants now, 16 under way, 1 of them phase 3. Hypertension · University of Alabama at Birmingham.
Among the 44 studies in Hypertension by University of Alabama at Birmingham, this one is the 4th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2027, is one of 29 with no phase, reaches primary completion later than 15 of the 15 other live ones, and was the 44th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →13 of the 44 studies in Hypertension by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 60+
University of Alabama at Birmingham · Sites in United States
Ages 30–79 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18–55
University of Alabama at Birmingham · Sites in United States
Ages 18–89
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 2 · Phase 4 3
First in 1995; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 572 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 71 across the 38 interventional studies, 378 across the 6 observational. Of the 27 that completed or were terminated, 9 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
2 of the studies in Hypertension by University of Alabama at Birmingham that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT07760350University of Alabama at BirminghamAssessing the Feasibility of the "Heart Care Pairs" Intervention | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Hypertension by University of Alabama at Birmingham, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. The study will enroll 552 participants who are seen at the University of Alabama at Birmingham 1917 Dewberry Clinic and Vanderbilt Comprehensive Care Center. Half of the participants (276 patients) will be asked to measure blood pressure at home, and half of the participants (276 patients) will continue to receive usual care. Participants who measure blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 6 months.
For all participants:1. Participants will receive information on the importance of measuring blood pressure and ways to improve blood pressure. 2. Participants will complete questionnaires describing current socioeconomic position, medical history and healthcare needs. 3. Participants will come in for three research clinic visits to get blood pressure measured 3 months after enrollment in this study, and 6 months after enrollment in this study.
For participants asked to measure blood pressure at home: 1. Measure blood pressure twice a day at home, following the instructions provided. The study will provide participants with the device and send text message reminders twice a week. Participants will return the device at study visit 3 months from now. 2. Following the instructions provided, participants will talk to a pharmacist over the phone weekly to discuss blood pressure and medications. All medication changes will be discussed with a collaborating physician. 3. Participants will complete questionnaires and interviews on satisfaction with the program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
Behavioral: Remote Blood Pressure Monitoring + Telehealth
Participants receive usual care from providers to manage blood pressure
Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
Also known as: Intervention group
Total Number of Enrolled Participants with Blood Pressure Control
The number of enrolled participants with blood pressure control
Time frame: Time Frame: 12 weeks (3 months) from randomization
Number of Participants in the Intervention with Patient-Reported Outcomes
The number of participants with completed qualitative interviews and surveys regarding intervention adherence and satisfaction. The survey will assess intervention adherence and satisfaction using the following scales: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and the Feasibility of Intervention Measure (FIM). The AIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better acceptability while the lower total score indicates worse acceptability. The IAM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better appropriateness while the lower total score indicates worse appropriateness. The FIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better feasibility while the lower total score indicates worse feasibility.
Time frame: Time Frame: 24 weeks (6 months) from randomization
No study locations are listed for this record.
Plan to share: No — While the investigators do not anticipate generating research tools, the investigators are committed to adhering to the National Institutes of Health (NIH) Research Tools Policy to ensure that any resources developed under this award are readily available to qualified researchers. If an NIH-defined research tool is developed, the investigators will collaborate with University of Alabama at Birmingham Commercialization and Licensing Office and all participating institutions to define ownership, protect intellectual property, and establish a dissemination strategy that ensures appropriate access and compliance with NIH guidelines.
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Feb 2031, 48 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 48 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →